Synergistic retention strategy of RGD active targeting and radiofrequency-enhanced permeability for intensified RF &amp; chemotherapy synergistic tumor treatment

Zhang, Kun; Li, Pei; He, Yaping; Bo, Xiao-Wan; Li, Xiao‐Long; Li, Dandan; Chen, Hangrong; Xu, Hui‐Xiong

doi:10.1016/j.biomaterials.2016.05.014

Cited by 45 publications

(28 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, cell viability test revealed that PFTBA@HSA showed no toxicity on tissue cells, including normal cells and tumor cells ( Figure S2 ). The oxygen-carrying and oxygen-release capabilities of PFTBA@HSA were evaluated using an oxygen meter to measure the dissolved oxygen concentration in aqueous solution 26 , 34 , 35 . The dissolved oxygen concentration in PFTBA@HSA at 25 ℃ under 1 atm was approximately 500 μM 13 , which is consistent with results reported in the literature ( Figure 2 E ).…”

Section: Resultsmentioning

confidence: 99%

Two-stage oxygen delivery for enhanced radiotherapy by perfluorocarbon nanoparticles

et al. 2018

View full text Add to dashboard Cite

Tumors are usually hypoxic, which limits the efficacy of current tumor therapies, especially radiotherapy in which oxygen is essential to promote radiation-induced cell damage. Herein, by taking advantage of the ability of perfluorocarbon (PFC) to promote red blood cell penetration, we developed a simple but effective two-stage oxygen delivery strategy to modulate the hypoxic tumor microenvironment using PFC nanoparticles.Methods: We first examined the two-stage oxygen delivery ability of PFC nanoparticles on relieving tumor hypoxia through platelet inhibition. To evaluate the effect of PFC nanoparticles on radiation sensitization, CT26 tumor and SUM49PT tumor model were used.Results: In this study, PFC was encapsulated into albumin and intravenously injected into tumor-bearing mice without hyperoxic breathing. After accumulation in the tumor, PFC nanoparticles rapidly released the oxygen that was physically dissolved in PFC as the first-stage of oxygen delivery. Then, PFC subsequently promoted red blood cell infiltration, which further released O2 as the second-stage of oxygen delivery.Conclusion: The hypoxic tumor microenvironment was rapidly relieved via two-stage oxygen delivery, effectively increasing radiotherapy efficacy. The safety of all substances used in this study has been clinically demonstrated, ensuring that this simple strategy could be rapidly and easily translated into clinical applications to solve the clinical problems associated with tumor hypoxia.

show abstract

Section: Resultsmentioning

confidence: 99%

Two-stage oxygen delivery for enhanced radiotherapy by perfluorocarbon nanoparticles

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Before treatment, administration of antiangiogenic therapy can help to remove extra capillaries and abnormal blood vessels leading to a reduction in the pressure of the interstitial fluid [ 239 , 240 , 241 , 242 ]. Other suggestions include damaging already existing blood vessels leading to solid tumor vessel permeability and increased drug delivery [ 184 , 243 , 244 , 245 ]. It should be recalled however that several strategies that target tumors inadvertently affect normal tissues as well.…”

Section: Strategies To Overcome Chemoresistancementioning

confidence: 99%

The Role of Tumor Microenvironment in Chemoresistance: To Survive, Keep Your Enemies Closer

Senthebane

Rowe

Thomford

et al. 2017

IJMS

314

303

View full text Add to dashboard Cite

Chemoresistance is a leading cause of morbidity and mortality in cancer and it continues to be a challenge in cancer treatment. Chemoresistance is influenced by genetic and epigenetic alterations which affect drug uptake, metabolism and export of drugs at the cellular levels. While most research has focused on tumor cell autonomous mechanisms of chemoresistance, the tumor microenvironment has emerged as a key player in the development of chemoresistance and in malignant progression, thereby influencing the development of novel therapies in clinical oncology. It is not surprising that the study of the tumor microenvironment is now considered to be as important as the study of tumor cells. Recent advances in technological and analytical methods, especially ‘omics’ technologies, has made it possible to identify specific targets in tumor cells and within the tumor microenvironment to eradicate cancer. Tumors need constant support from previously ‘unsupportive’ microenvironments. Novel therapeutic strategies that inhibit such microenvironmental support to tumor cells would reduce chemoresistance and tumor relapse. Such strategies can target stromal cells, proteins released by stromal cells and non-cellular components such as the extracellular matrix (ECM) within the tumor microenvironment. Novel in vitro tumor biology models that recapitulate the in vivo tumor microenvironment such as multicellular tumor spheroids, biomimetic scaffolds and tumor organoids are being developed and are increasing our understanding of cancer cell-microenvironment interactions. This review offers an analysis of recent developments on the role of the tumor microenvironment in the development of chemoresistance and the strategies to overcome microenvironment-mediated chemoresistance. We propose a systematic analysis of the relationship between tumor cells and their respective tumor microenvironments and our data show that, to survive, cancer cells interact closely with tumor microenvironment components such as mesenchymal stem cells and the extracellular matrix.

show abstract

“…Amphiphilic oligopeptides containing RGD are also promising candidates to load chemotherapeutic drugs via self‐assembly . To make RGD‐containing peptides less susceptible to chemical and enzymatic degradation, cyclization strategy has been introduced and cyclic RGD (cRGD) oligopeptides have been springing up for peptide‐mediated targeted therapy . Recently, Chen et al decorated disulfide (SS)‐containing poly(vinyl alcohol) nanogel with cRGD for the targeted treatment of integrin‐overexpressed human glioblastoma .…”

Section: Positive Targetingmentioning

confidence: 99%

Recent Advances in Targeted Tumor Chemotherapy Based on Smart Nanomedicines

Qin

Zhang

2018

Small

101

View full text Add to dashboard Cite

Efficacy and safety of chemotherapeutic drugs constitute two major criteria in tumor chemotherapy. Nanomedicines with tumor-targeted properties hold great promise for improving the efficacy and safety. To design targeted nanomedicines, the pathological characteristics of tumors are extensively and deeply excavated. Here, the rationale, principles, and advantages of exploiting these pathological characteristics to develop targeted nanoplatforms for tumor chemotherapy are discussed. Homotypic targeting with the ability of self-recognition to source tumors is reviewed individually. In the meanwhile, the limitations and perspective of these targeted nanomedicines are also discussed.

show abstract

Synergistic retention strategy of RGD active targeting and radiofrequency-enhanced permeability for intensified RF & chemotherapy synergistic tumor treatment

Cited by 45 publications

References 46 publications

Two-stage oxygen delivery for enhanced radiotherapy by perfluorocarbon nanoparticles

Two-stage oxygen delivery for enhanced radiotherapy by perfluorocarbon nanoparticles

The Role of Tumor Microenvironment in Chemoresistance: To Survive, Keep Your Enemies Closer

Recent Advances in Targeted Tumor Chemotherapy Based on Smart Nanomedicines

Contact Info

Product

Resources

About